Pfizer, the leading pharmaceutical company, recognizes synergies with a private biotechnology firm, Ambit Biosciences, based in San Diego. Pfizer is deciding between trying to acquire Ambit and developing a collaborative relationship with it. What is one major problem each that acquisitions and alliances typically run into? Assuming that Ambit is a willing acquisition target and alliance partner, what are two factors that Pfizer should consider while choosing whether to acquire Ambit or collaborate with it?